RETAVASE
LOE Approachingreteplase
BLAVIAL
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Retavase (reteplase) is a recombinant plasminogen activator indicated for acute myocardial infarction (AMI) to improve ventricular function and reduce mortality. It works by converting plasminogen to plasmin, which dissolves fibrin clots in coronary arteries. This thrombolytic agent is administered intravenously as a bolus injection.
LOE Approaching
As LOE approaches, expect smaller team size and reduced investment in new initiatives; focus shifts to defending market position against generic/biosimilar entrants.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
Started May 2026
220 enrolled
Acute Ischemic Stroke
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
Started Aug 2002
2,461 enrolled
Myocardial Infarction
Career Relevance
Working on Retavase offers limited career growth given its LOE-approaching status and minimal linked job openings (0). Professionals joining this product should expect focus on defending market position, managing decline, and supporting transition to biosimilar competition. This role is better suited to mid-career professionals seeking stability rather than high-growth environments.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.